Our portfolio companies

Portfolio Our portfolio companies

Replimune

Replimune

Developing the next generation of oncolytic immunotherapy.

Replimune, headquartered in Oxford UK and with a significant presence in Cambridge, MA, was founded in April 2015 to develop the next generation of "oncolytic immunotherapies" for the treatment of cancer. Replimune is developing a potent and versatile patient non-specific universal neoantigen vaccination approach for the treatment of solid tumors, based on its Immulytic oncolytic immunotherapy platform."

  • Industry Biotech